Literature DB >> 22584848

Interleukin-10 of red nucleus plays anti-allodynia effect in neuropathic pain rats with spared nerve injury.

Zhi-Hong Wang1, Xiao-Yan Zeng, Shui-Ping Han, Gui-Xiang Fan, Jun-Yang Wang.   

Abstract

Our previous studies have shown that pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1beta (IL-1β) in red nucleus (RN) are involved in the development of neuropathic pain and play facilitated roles on the mechanical allodynia induced by peripheral nerve injury. The current study was designed to evaluate the expression and effect of IL-10, an anti-inflammatory cytokine, in the RN of rats with spared nerve injury (SNI). Immunohistochemical staining results demonstrated when 3 weeks after SNI, the expression level of IL-10 in the contralateral RN of SNI rats was apparently higher than those of sham-operated and normal rats. To further study the effect of IL-10 in the development of neuropathic pain, different doses of IL-10 (1.0, 0.5 and 0.1 μg/μl) were microinjected respectively into the RN contralateral to the nerve injury side of SNI rats. Results demonstrated that higher doses of IL-10 (1.0 and 0.5 μg/μl) significantly attenuated the mechanical allodynia of neuropathic rats, while 0.1 μg/μl of IL-10 did not show any analgesic effect. These results suggest that IL-10 of RN participates in the development of neuropathic pain and plays inhibitory roles on the mechanical allodynia induced by SNI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584848     DOI: 10.1007/s11064-012-0795-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  45 in total

Review 1.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

2.  Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia.

Authors:  M Sawada; A Suzumura; H Hosoya; T Marunouchi; T Nagatsu
Journal:  J Neurochem       Date:  1999-04       Impact factor: 5.372

3.  Chronic neuropathic pain-like behavior correlates with IL-1β expression and disrupts cytokine interactions in the hippocampus.

Authors:  Adriana Del Rey; Hau-Jie Yau; Anke Randolf; Maria V Centeno; Johannes Wildmann; Marco Martina; Hugo O Besedovsky; Vania A Apkarian
Journal:  Pain       Date:  2011-10-26       Impact factor: 6.961

4.  Bilateral changes of IL-10 protein in lumbar and cervical dorsal root ganglia following proximal and distal chronic constriction injury of peripheral nerve.

Authors:  R Jancalek; I Svizenska; I Klusakova; P Dubovy
Journal:  Neurosci Lett       Date:  2011-07-03       Impact factor: 3.046

5.  Efficient analysis of experimental observations.

Authors:  W J Dixon
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

6.  Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10.

Authors:  Erin D Milligan; Stephen J Langer; Evan M Sloane; Lin He; Julie Wieseler-Frank; Kevin O'Connor; David Martin; John R Forsayeth; Steven F Maier; Kirk Johnson; Raymond A Chavez; Leslie A Leinwand; Linda R Watkins
Journal:  Eur J Neurosci       Date:  2005-04       Impact factor: 3.386

7.  Cytokine involvement in dynorphin-induced allodynia.

Authors:  T M Laughlin; J R Bethea; R P Yezierski; G L Wilcox
Journal:  Pain       Date:  2000-02       Impact factor: 6.961

8.  Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat.

Authors:  J A Plunkett; C G Yu; J M Easton; J R Bethea; R P Yezierski
Journal:  Exp Neurol       Date:  2001-03       Impact factor: 5.330

9.  Nerve growth factor of red nucleus involvement in pain induced by spared nerve injury of the rat sciatic nerve.

Authors:  Yuan-Yuan Jing; Jun-Yang Wang; Xiao-Li Li; Zhi-Hong Wang; Liu Pei; Ming-Ming Pan; Xiao-Ping Dong; Gui-Xiang Fan; Yu-Kang Yuan
Journal:  Neurochem Res       Date:  2009-03-15       Impact factor: 3.996

10.  Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain.

Authors:  Lisa C Loram; Jacqueline A Harrison; Evan M Sloane; Mark R Hutchinson; Paige Sholar; Frederick R Taylor; Debra Berkelhammer; Benjamen D Coats; Stephen Poole; Erin D Milligan; Steven F Maier; Jayson Rieger; Linda R Watkins
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

View more
  10 in total

1.  The Red Nucleus Interleukin-6 Participates in the Maintenance of Neuropathic Pain Induced by Spared Nerve Injury.

Authors:  Cui-Ping Ding; Yu-Shun Xue; Jing Yu; Yi-Jie Guo; Xiao-Yan Zeng; Jun-Yang Wang
Journal:  Neurochem Res       Date:  2016-08-03       Impact factor: 3.996

Review 2.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

3.  The Red Nucleus TNF-α Participates in the Initiation and Maintenance of Neuropathic Pain Through Different Signaling Pathways.

Authors:  Qian Zhang; Jing Yu; Jing Wang; Cui-Ping Ding; Shui-Ping Han; Xiao-Yan Zeng; Jun-Yang Wang
Journal:  Neurochem Res       Date:  2015-05-08       Impact factor: 3.996

4.  IL-10 and IL-1β mediate neuropathic-pain like behavior in the ventrolateral orbital cortex.

Authors:  Qingdong Shao; Yufei Li; Qiang Wang; Jianning Zhao
Journal:  Neurochem Res       Date:  2015-01-24       Impact factor: 3.996

5.  Tissue-resident glial cells associate with tumoral vasculature and promote cancer progression.

Authors:  Beatriz G S Rocha; Caroline C Picoli; Bryan O P Gonçalves; Walison N Silva; Alinne C Costa; Michele M Moraes; Pedro A C Costa; Gabryella S P Santos; Milla R Almeida; Luciana M Silva; Youvika Singh; Marcelo Falchetti; Gabriela D A Guardia; Pedro P G Guimarães; Remo C Russo; Rodrigo R Resende; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Alexandre Kanashiro; Helder I Nakaya; Edroaldo L Rocha; Pedro A F Galante; Akiva Mintz; Paul S Frenette; Alexander Birbrair
Journal:  Angiogenesis       Date:  2022-10-01       Impact factor: 10.658

Review 6.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

7.  μ-Opioid activation in the midbrain during migraine allodynia - brief report II.

Authors:  Thiago D Nascimento; Marcos F DosSantos; Sarah Lucas; Hendrik van Holsbeeck; Misty DeBoer; Eric Maslowski; Tiffany Love; Ilkka K Martikainen; Robert A Koeppe; Yolanda R Smith; Jon-Kar Zubieta; Alexandre F DaSilva
Journal:  Ann Clin Transl Neurol       Date:  2014-06-01       Impact factor: 4.511

8.  Red Nucleus Interleukin-6 Evokes Tactile Allodynia in Male Rats Through Modulating Spinal Pro-inflammatory and Anti-inflammatory Cytokines.

Authors:  Qing-Qing Yang; Hao-Nan Li; Yu-Tong Xia; Xue Tian; Fan Feng; Jian Yang; Ya-Li Xu; Juan Guo; Xiao-Qi Li; Jun-Yang Wang; Xiao-Yan Zeng
Journal:  Front Mol Neurosci       Date:  2022-04-08       Impact factor: 5.639

9.  Gabapentin enhances the morphine anti-nociceptive effect in neuropathic pain via the interleukin-10-heme oxygenase-1 signalling pathway in rats.

Authors:  Yu-Hua Bao; Quan-Hong Zhou; Rui Chen; Hao Xu; Lu-Lu Zeng; Xin Zhang; Wei Jiang; Dong-Ping Du
Journal:  J Mol Neurosci       Date:  2014-02-27       Impact factor: 3.444

10.  Red nucleus IL-33 facilitates the early development of mononeuropathic pain in male rats by inducing TNF-α through activating ERK, p38 MAPK, and JAK2/STAT3.

Authors:  Hao-Nan Li; Qing-Qing Yang; Wen-Tao Wang; Xue Tian; Fan Feng; Shu-Ting Zhang; Yu-Tong Xia; Jia-Xue Wang; Yuan-Wu Zou; Jun-Yang Wang; Xiao-Yan Zeng
Journal:  J Neuroinflammation       Date:  2021-07-05       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.